Danish biotechnology company Bavarian Nordic has announced in a press release that an abstract regarding the company's prostate vaccine Prostvac, currently under development, has been accepted for presentation at the 2009 American Society of Clinical Oncology Annual Meeting in the USA in May. This is considered by the pharmaceutical industry to be a major international acknowledgment, daily financial newspaper Børsen reported.
Data from a Phase 2 study of 125 patients with advanced prostate cancer will be presented at the meeting by Professor Philip Kantoff of Harvard Medical School and the Dana-Farber Cancer Institute, which is the principal investigator of the study.
Bavarian Nordic has previously reported data from this study, showing that patients receiving Prostvac had a longer overall survival by 8.5 months compared to the control group.
Medical consultant Michael Borre from University Hospital Skejby in Denmark commented: "When it was discovered that chemotherapy could prolong life [for patients with prostate cancer - Ed] by two or three months, there was a lot of enthusiasm. In this case, life expectancy is apparently extended even longer, and it is worth noting that the vaccine has been tested on people who are very ill, so you can imagine an even better effect when Prostvac is given earlier in the course of the disease."
Bavarian Nordic hopes to start phase III trial of Prostvac in 2010.
Headquartered in Denmark, Bavarian Nordic develops and produces innovative vaccines to prevent and treat life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic employs over 260 people and has operations in Germany, the US and Singapore. Bavarian Nordic's partners include Pharmexa, Impfstoffwerk Dessau-Tornau (IDT) and Vaccine Solutions.